A Second Look: Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with an endocrinologist

Executed on:Sep 13, 2023 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of PittsburghDirector of Endocrinology and Metabolism Clinical Research Core and Translational Research Center at UPMC.
Treats 800- 900 obese patients per year who are at risk for major adverse cardiac events.
Clinical interests are in the areas of diabetes and general endocrinology; Research interests in the etiology and treatment of insulin resistance in humans, medications that improve insulin resistance and beta cell function, and is currently investigating the pathogenesis of pancreatitis-related diabetes to identify new possibilities of prevention and treatment. 

Interview Goal

On this call, we will be digging into the results from the SELECT trial of WEGOVY (semaglutide) and discussing it's potential of reducing the risk of major adverse cardiovascular events (MACE) for obese or overweight patients with an endocrinologist.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.